Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHG Pharmaceutical JSCSTC:DHG -0.11%77 EV-to-EBITDA is 8.05 as of Aug. 03, 2026, which is 30% below its 10-year median of 11.47. GuruFocus rates STC:DHG with a GF Score™ of 77/100 and a GF Value™ of ₫113,447.74 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 746 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 70.78% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DHG Pharmaceutical JSC's enterprise value is ₫10,407,739 Mil.
DHG Pharmaceutical JSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₫1,292,530 Mil. Therefore, DHG Pharmaceutical JSC's EV-to-EBITDA for today is 8.05.
The historical rank and industry rank for DHG Pharmaceutical JSC's EV-to-EBITDA or its related term are showing as below:
STC:DHG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.46 Med: 11.47 Max: 19.37
Current: 8.05
During the past 13 years, the highest EV-to-EBITDA of DHG Pharmaceutical JSC was 19.37. The lowest was 7.46. And the median was 11.47.
STC:DHG's EV-to-EBITDA is ranked better than 70.78% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.015
vs STC:DHG: 8.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DHG Pharmaceutical JSC's PE Ratio (TTM) for today is calculated as:
DHG Pharmaceutical JSC's share price for today is ₫92600.00.
DHG Pharmaceutical JSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫7473.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's EV-to-EBITDA falls into.
DHG Pharmaceutical JSC's current Enterprise Value is ₫10,407,739 Mil.
DHG Pharmaceutical JSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫1,292,530 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHG Pharmaceutical JSC (STC:DHG) has a EV-to-EBITDA of 8.05 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DHG Pharmaceutical JSC. This is 30% below median its historical median of 11.47. Over the past decade, DHG Pharmaceutical JSC's EV-to-EBITDA has ranged from 7.46 to 19.37. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #218 out of 746 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is DHG Pharmaceutical JSC's EV-to-EBITDA too high?
DHG Pharmaceutical JSC's current EV-to-EBITDA of 8.05 is 30% below median its 10-year median of 11.47. Over the past 10 years, this metric has ranged from a low of 7.46 to a high of 19.37. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. DHG Pharmaceutical JSC's value of 8.05 is 38.1% below this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #218 out of 746 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, DHG Pharmaceutical JSC has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #218 out of 746 companies for EV-to-EBITDA. This puts DHG Pharmaceutical JSC in the upper half of its industry. The industry median EV-to-EBITDA is 13.02. DHG Pharmaceutical JSC's value of 8.05 is 38.1% below this benchmark. Historically, DHG Pharmaceutical JSC's own EV-to-EBITDA has ranged from 7.46 to 19.37 over the past decade. While the company's 10-year median is 11.47 vs. the industry median of 13.02, DHG Pharmaceutical JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current EV-to-EBITDA of 8.05 is 38.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DHG Pharmaceutical JSC. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current EV-to-EBITDA is 8.05, which is 30% below median its own 10-year median of 11.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,447.74, compared to a current price of ₫92,600.00 — trading 18.4% below its estimated fair value. The current EV-to-EBITDA is 8.05, which is 30% below median its 10-year median of 11.47 and 38.1% below the Drug Manufacturers industry median of 13.02. DHG Pharmaceutical JSC's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current EV-to-EBITDA is 8.05 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫92,600.00 is trading 18.4% below its estimated GF Value™ of ₫113,447.74.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
EV-to-EBITDA: 8.05 (30% below median its 10-year median of 11.47)
GF Value™: ₫113,447.74 vs. price of ₫92,600.00 (18.4% below fair value)
Industry Position: 38.1% below the Drug Manufacturers median (#218 of 746)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
77GF Score
Get the complete analysis for STC:DHG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
